119 related articles for article (PubMed ID: 27792298)
21. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
22. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
Cardozo L; Hessdörfer E; Milani R; Arañó P; Dewilde L; Slack M; Drogendijk T; Wright M; Bolodeoku J;
BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175
[TBL] [Abstract][Full Text] [Related]
23. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
[TBL] [Abstract][Full Text] [Related]
24. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
25. Trospium chloride treatment of overactive bladder.
Biastre K; Burnakis T
Ann Pharmacother; 2009 Feb; 43(2):283-95. PubMed ID: 19193592
[TBL] [Abstract][Full Text] [Related]
26. Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials.
Colli E; Parazzini F; Olivieri L; Cipriani S; Bertozzi R; Meschia M; Montorsi F
Eur Urol; 2007 Aug; 52(2):525-30. PubMed ID: 17449169
[TBL] [Abstract][Full Text] [Related]
27. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial.
Karram MM; Toglia MR; Serels SR; Andoh M; Fakhoury A; Forero-Schwanhaeuser S
Urology; 2009 Jan; 73(1):14-8. PubMed ID: 18995887
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.
Khullar V; Amarenco G; Angulo JC; Cambronero J; Høye K; Milsom I; Radziszewski P; Rechberger T; Boerrigter P; Drogendijk T; Wooning M; Chapple C
Eur Urol; 2013 Feb; 63(2):283-95. PubMed ID: 23182126
[TBL] [Abstract][Full Text] [Related]
29. The efficacy and safety of Vibegron in treating overactive bladder: A systematic review and pooled analysis of randomized controlled trials.
Shi H; Chen H; Zhang Y; Cui Y
Neurourol Urodyn; 2020 Jun; 39(5):1255-1263. PubMed ID: 32421908
[TBL] [Abstract][Full Text] [Related]
30. Urinary urgency: a review of its assessment as the key symptom of the overactive bladder syndrome.
Abrams P; Chapple CR; Jünemann KP; Sharpe S
World J Urol; 2012 Jun; 30(3):385-92. PubMed ID: 21853323
[TBL] [Abstract][Full Text] [Related]
31. Clinical Efficacy and Tolerability of the Nicotinic Channel Modulator Dexmecamylamine in Subjects with Overactive Bladder.
Chancellor M; Versi E; Dvergsten C; Toler S
J Urol; 2015 Nov; 194(5):1329-35. PubMed ID: 26073872
[TBL] [Abstract][Full Text] [Related]
32. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity.
Nitti VW; Rovner ES; Bavendam T
BJU Int; 2010 May; 105(9):1268-75. PubMed ID: 19889062
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of Daily Low-dose Tadalafil for Treating Overactive Bladder: Results of a Randomized, Double-blind, Placebo-controlled Trial.
Chen H; Wang F; Yu Z; Zhang Y; Liu C; Dai S; Chen B; Lv J
Urology; 2017 Feb; 100():59-64. PubMed ID: 27845219
[TBL] [Abstract][Full Text] [Related]
34. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial.
Wagg A; Khullar V; Marschall-Kehrel D; Michel MC; Oelke M; Darekar A; Bitoun CE; Weinstein D; Osterloh I
J Am Geriatr Soc; 2013 Feb; 61(2):185-93. PubMed ID: 23350833
[TBL] [Abstract][Full Text] [Related]
35. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC
Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
[TBL] [Abstract][Full Text] [Related]
36. Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder.
Rovner ES; Rackley R; Nitti VW; Wang JT; Guan Z;
Urology; 2008 Sep; 72(3):488-93. PubMed ID: 18639327
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
[TBL] [Abstract][Full Text] [Related]
38. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome.
Nitti VW; Dmochowski R; Sand PK; Forst HT; Haag-Molkenteller C; Massow U; Wang J; Brodsky M; Bavendam T
J Urol; 2007 Dec; 178(6):2488-94. PubMed ID: 17937959
[TBL] [Abstract][Full Text] [Related]
39. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
[TBL] [Abstract][Full Text] [Related]
40. Duloxetine compared with placebo for treating women with symptoms of overactive bladder.
Steers WD; Herschorn S; Kreder KJ; Moore K; Strohbehn K; Yalcin I; Bump RC;
BJU Int; 2007 Aug; 100(2):337-45. PubMed ID: 17511767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]